Results of an open label study on omega-3 PUFA supplementation found a small but transient effect on gut microbiota that could warrant future research.
Atrial fibrillation recurrence remains a challenge amidst significant advances in managing stroke risk. Could the CHA2DS2-VASc score help?
How well do you know your CV outcomes trial data for novel type 2 diabetes drugs? Your answers to these 8 questions will tell.
SGLT-2 inhibitors appear to have a more consistent effect on prevention of HF and renal outcomes than on atherosclerotic CV events, say study authors.
Among lipid clinic patients, actual EPA+DHA supplement intake was <50% of prescribed dosage, according to the first study to look at the association.
Findings from REDUCE-IT are the first to show that EPA lowers the relative risk of hard cardiovascular endpoints. Johns Hopkins' Seth Martin, MD, and colleagues put the trial in perspective.
Cardiorenal syndrome has 5 subtypes that are each sbudivided as well. This quiz focuses on type 4--so cardiologists and nephrologists, unite!
Fish oil or fish for CV protection? It's a well studied yet unresolved question. Highlights, here, of the ASCEND study and all those that came before.
Patients with renal disease are poorly represented in studies of treatment for STEMI but, a new study finds, are at much greater risk for MACE and death.
Either one is fine – the point is to make sure the practice stays a step ahead of the next new drug class causing the problem.